Your session is about to expire
← Back to Search
Immunomodulator
ABX196 for Hepatocellular Carcinoma
Phase 1 & 2
Recruiting
Led By Darren SIGAL, MD
Research Sponsored by Abivax S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug, ABX196, to see if it is safe and effective in treating hepatocellular carcinoma when used with nivolumab.
Eligible Conditions
- Hepatocellular Carcinoma
- Liver Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of adverse events (AEs)
Secondary study objectives
Objective Response Rate (ORR)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ABX196Experimental Treatment1 Intervention
IM injection of 0.1, 0.2, and 0.4 µg of ABX196
Find a Location
Who is running the clinical trial?
Abivax S.A.Lead Sponsor
21 Previous Clinical Trials
4,399 Total Patients Enrolled
C3 Research AssociatesUNKNOWN
2 Previous Clinical Trials
96 Total Patients Enrolled
Darren SIGAL, MDPrincipal InvestigatorScripps Clinic/Scripps MD Anderson Cancer Center
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger